Abstract
The signaling pathways which contribute to neuronal death during development, aging and disease have been extensively studied. While initial efforts focused on developmental death, increasing evidence suggests that mitogenactivated protein kinase pathways play a role in human pathology. In particular, the c-Jun N-terminal kinases (JNKs), mitogen- activated protein kinases activated by extracellular stimuli including stress, are a major focus. Knock-out mouse studies have demonstrated that removing particular JNK genes can reduce the severity in various disease scenarios, including those which are used to model Parkinsons disease and cerebral ischemia. In addition, activation of JNKs can be seen in human disease tissue. In this review we bring together the evidence for JNK being an important regulator of neuronal loss and outline the advancement of small molecule inhibitors for future therapeutic intervention.
Keywords: Mitogen-activated protein kinase, c-Jun N-terminal kinase, phosphorylation, neurodegeneration, Alzheimer's disease, Parkinson's disease, neuroprotection
CNS & Neurological Disorders - Drug Targets
Title: MAP Kinase Pathways in Neuronal Cell Death
Volume: 7 Issue: 1
Author(s): Karen L. Philpott and Laura Facci
Affiliation:
Keywords: Mitogen-activated protein kinase, c-Jun N-terminal kinase, phosphorylation, neurodegeneration, Alzheimer's disease, Parkinson's disease, neuroprotection
Abstract: The signaling pathways which contribute to neuronal death during development, aging and disease have been extensively studied. While initial efforts focused on developmental death, increasing evidence suggests that mitogenactivated protein kinase pathways play a role in human pathology. In particular, the c-Jun N-terminal kinases (JNKs), mitogen- activated protein kinases activated by extracellular stimuli including stress, are a major focus. Knock-out mouse studies have demonstrated that removing particular JNK genes can reduce the severity in various disease scenarios, including those which are used to model Parkinsons disease and cerebral ischemia. In addition, activation of JNKs can be seen in human disease tissue. In this review we bring together the evidence for JNK being an important regulator of neuronal loss and outline the advancement of small molecule inhibitors for future therapeutic intervention.
Export Options
About this article
Cite this article as:
Philpott L. Karen and Facci Laura, MAP Kinase Pathways in Neuronal Cell Death, CNS & Neurological Disorders - Drug Targets 2008; 7(1) . https://dx.doi.org/10.2174/187152708783885129
DOI https://dx.doi.org/10.2174/187152708783885129 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
A Novel Tetradentate Ruthenium(II) Complex Containing Tris(2- pyridylmethyl)amine (tpa) as an Inhibitor of Beta-Amyloid Fibrillation
Current Alzheimer Research Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Induction of Cellular Oxidative Stress by the β-amyloid Peptide Involved in Alzheimers disease
Protein & Peptide Letters Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Proton Magnetic Resonance Spectroscopy Changes After Antipsychotic Treatment
Current Medicinal Chemistry Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Anti-Proliferative Activity of Standardized Methanol Extract of Coscinium fenestratum and Its Major Constituent, Berberine, Against Nasopharyngeal Carcinoma Cells
The Natural Products Journal FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology γ-AApeptides as a New Class of Peptidomimetics: Design, Synthesis, and Applications
Current Topics in Medicinal Chemistry Natural Products as Anticancer Agents
Current Drug Targets Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Possible Involvement of Programmed Cell Death Pathways in the Neuroprotective Action of Polyphenols
Current Alzheimer Research Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science